Abstract
It is estimated that 50% of patients who have undergone ileal pouch – anal anastomosis (IPAA) surgery for UC will develop at least one episode of pouchitis. The risk of developing pouchitis is much higher in patients with preoperative extraintestinal manifestations and primary sclerosing cholangitis. In acute pouchtis metronidazole or ciprofloxacin have shown efficacy, however there is some evidence that ciprofloxacin may have better and has less toxic. In patients with chronic pouchitis antibiotics are less effective, and maintenance therapy may be required. In cases of refractoriness to conventional therapy a combination of two antibiotics for a prolonged period or infliximab may be effective. Starting maintenance treatment with highly concentrated probiotics is recommended as primary and secondary prophylaxis.
Keywords: Pouchitis, Antibiotics, Treatment, Probiotics, Tumor Necrosis Factor, Sulfate reducing bacteria, ESBL, Azathioprine
Current Drug Targets
Title: How to Manage Pouchitis in Ulcerative Colitis?
Volume: 12 Issue: 10
Author(s): F. Magro, S. Lopes, S. Rodrigues and I. Azevedo
Affiliation:
Keywords: Pouchitis, Antibiotics, Treatment, Probiotics, Tumor Necrosis Factor, Sulfate reducing bacteria, ESBL, Azathioprine
Abstract: It is estimated that 50% of patients who have undergone ileal pouch – anal anastomosis (IPAA) surgery for UC will develop at least one episode of pouchitis. The risk of developing pouchitis is much higher in patients with preoperative extraintestinal manifestations and primary sclerosing cholangitis. In acute pouchtis metronidazole or ciprofloxacin have shown efficacy, however there is some evidence that ciprofloxacin may have better and has less toxic. In patients with chronic pouchitis antibiotics are less effective, and maintenance therapy may be required. In cases of refractoriness to conventional therapy a combination of two antibiotics for a prolonged period or infliximab may be effective. Starting maintenance treatment with highly concentrated probiotics is recommended as primary and secondary prophylaxis.
Export Options
About this article
Cite this article as:
Magro F., Lopes S., Rodrigues S. and Azevedo I., How to Manage Pouchitis in Ulcerative Colitis?, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818144
DOI https://dx.doi.org/10.2174/138945011796818144 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recombinant Salmonella Vaccination Technology and Its Application to Human Bacterial Pathogens
Current Pharmaceutical Biotechnology Zevalin™: 90Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin ’ s Lymphoma
Current Pharmaceutical Biotechnology Purines as Neurotransmitters and Neuromodulators in Blood Vessels
Current Vascular Pharmacology Lysophospholipids: Their Generation, Physiological Role and Detection. Are They Important Disease Markers?
Mini-Reviews in Medicinal Chemistry Role of the Innate Immune System in Autoimmune Inflammatory Demyelination
Current Medicinal Chemistry Improved Brain Expression of Anti-Amyloid β scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Catiomer
Current Alzheimer Research The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Phenotyping and Genotyping of the Ryanodine Receptor-Associated Genetic Diseases Using Peripheral Lymphocytes
Current Pharmacogenomics The Cell Wall-Associated Proteins in the Dimorphic Pathogenic Species of Paracoccidioides
Current Protein & Peptide Science Monocytes, Macrophages and Other Inflammatory Mediators of Abdominal Aortic Aneurysm
Current Pharmaceutical Design Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design Enhancement of Immunoprotective Effect of CpG-ODN by Formulation with Polyphosphazenes Against E. coli Septicemia in Neonatal Chickens
Current Drug Delivery Cross-talk Between Exogenous Statins and Endogenous High-Density Lipoprotein in Anti-Inflammatory and Anti-Atherogenic Actions
Endocrine, Metabolic & Immune Disorders - Drug Targets Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways
Current Neuropharmacology Microparticles: A Pivotal Nexus in Vascular Homeostasis and Disease
Current Clinical Pharmacology Essential Oils Downregulate Pro-Inflammatory Cytokines and Nitric Oxide-Mediated Oxidative Stress in Alloxan-Induced Diabetogenic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Sertoli Cell Proteins in Immunomodulation
Protein & Peptide Letters Pathology of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design